At ASCO 2025, Matt Riordan, CEO of Putnam Associates, part of Inizio Advisory, shares expert insights on the future of cancer treatment, commercialization strategy, and accelerating the adoption of next-gen therapies across clinical settings.
Highlights
- Key challenge: ensuring adoption across both academic and community oncology
- Faster clinician and patient education = faster uptake of breakthrough drugs
- Real-world strategy behind the launch of the first CAR-T therapy
- AI in oncology: overhyped or underutilized? Why human judgment still matters
- Aligning medical, commercial, and access teams around a unified strategy
- Inizio’s integrated approach: turning strategy into action across the lifecycle
- Why the real win is accelerating access for patients—without delay